Bionano Genomics Announces the Launch of Version 6.1 of BioDiscovery’s NxClinical Software for Genome Analysis with Expanded Capabilities for Visualization, Interpretation and Reporting of Next-Generation Sequencing Data in Genetic Diseases and Cancer
17 December 2021 - 12:00AM
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping
(OGM) solutions on the Saphyr® system and the leading software
for genomic data visualization, interpretation and reporting, today
announced the launch of version 6.1 of BioDiscovery’s NxClinical
software with expanded capabilities for next-generation sequencing
(NGS) data in genetic diseases and cancer. NxClinical is an
industry-leading, platform-agnostic software solution, which
integrates NGS and microarray data designed to provide analysis,
visualization, interpretation and reporting of copy number variants
(CNV), single-nucleotide variants and absence of heterozygosity
across the genome in one consolidated view.
“This new version is designed to address requests from our
NxClinical customers around the world seeking to see more of what
matters in their NGS data,” commented Soheil Shams, PhD, Chief
Informatics Officer of Bionano Genomics. “We are committed to
helping customers reveal more clinically relevant variants from
genomic data across multiple platforms with a streamlined workflow
that can allow for optimal turnaround time. This software upgrade
represents another step further as we continue toward laying the
groundwork for our goal of integrating OGM data with NGS data to
provide what we believe can become the most comprehensive view of
genome variation.”
We believe version 6.1 significantly improves the ability of
NxClinical to detect more clinically relevant variants from NGS
data with the inclusion of uniparental disomy functionality and the
expanded sequence knowledgebase for visualization and reporting of
relevant genomic variants. In addition, data interpretation has
been streamlined with the automated annotation of clinically
relevant variants using the American College of Medical Genetics
and Genomics (ACMG) technical standards. This feature automatically
calculates the relevance for many of the evidence categories
described by the ACMG technical standards for CNV interpretation,
which can simplify data interpretation and reduce time to
reportable result.
“At Bionano, we are working to transform the way the world sees
the genome to elevate human health and wellness,” said Erik
Holmlin, PhD, President and CEO of Bionano Genomics. “Software is
the primary way our customers interact with their data and
experience our products. Our goal is to increase the number of
Bionano subscribers using NxClinical software to create a network
effect where customers can obtain more meaningful results from
their NGS and microarray data today so that in the future they can
more easily implement OGM within the same software tool to see more
genomic variants that matter.”
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the ability and
utility of NxClinical software to help visualize, interpret and
report NGS data in genetic diseases and cancer; the ability of
NxClinical software to integrate OGM data with NGS data to provide
a comprehensive view of genome variation; the ability of NxClinical
software to create a network effect that combines the synergies of
NGS and microarray data to allow implementation of OGM within the
same software. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive products; failure of the new version of
NxClinical to perform as intended; the effect on our software of
cyber attacks, viruses and the like; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2020 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024